

PRESS RELEASE

Heidelberg Pharma Reports Outcome Of Annual General Meeting

Ladenburg, Germany, 26 June 2018 – Heidelberg Pharma AG (FSE: WL6) today announced that the shareholders of the Company approved all resolutions of the administration with large majorities during the Annual General Meeting today.

Agenda / Resolutions:

Item 1: Presentation of the financial statements 2017

Item 2 and 3: Resolution on the formal approval of the Executive Management Board members and the Supervisory Board members for the financial year 2017

Item 4: Appointment of Deloitte GmbH Wirtschaftsprüfungsgesellschaft as auditors and group auditors for the financial year 2017/2018

Item 5: Resolution to create new Authorized Capital 2018/I and to amend the Articles of Association correspondingly

Item 6: Resolution on the authorization to grant subscription rights (stock options) to members of the Executive Management Board of the Company and employees of the Company or affiliates (Heidelberg Pharma 2018 Stock Option Plan), on the reduction of Contingent Capital II, on the creation of Contingent Capital 2018/I to satisfy the Heidelberg Pharma 2018 Stock Option Plan, and on corresponding amendments to the Articles of Association

Item 7: Resolution on the approval of the system for the remuneration of the members of the Executive Management Board

At the Annual General Meeting 2018, 80.40% of the current share capital were represented. The approval rates of the AGM for the proposed resolutions ranged from 99.70% to 99.99%.

Please find more information here: <http://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting/agm2018/>.

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma.

The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON[®] and REDECTANE[®], while RENCAREX[®] is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

Contact

Heidelberg Pharma AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
E-Mail: [investors\[at\]hdpharma.com](mailto:investors[at]hdpharma.com)
Schriesheimer Str. 101, 68526 Ladenburg

IR/PR support

MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Mobil: +49 160 9360 3022
E-Mail: [katja.arnold\[at\]mc-services.eu](mailto:katja.arnold[at]mc-services.eu)

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.